BiotechBull

Rigel Pharmaceuticals: Biotech Crisis or Opportunity?

Big pharma company is going to fork over large $ to license rights to R788....that efficacy data (ACR scores) are the best we have seen in any pipeline drug....

Rigel's Punishment May Prove Short-Sighted

I completly agree--and have seen enormous overreaction as a huge buying opportunity. A couple of quick thoughts:

- High probability Rigel will partner drug soon
- $442m is conservative--after 4-years on market and tons of safety data generated should be in $600-$800 range
-ACR20/50/70 (efficacy) is as good, if not better, than efficacy of current blockbusters TNF drugs (which also come with safety issues)
-Safety is the wild-card here,
-Actemra situation as analogue--drug has cholesterol safety issues (but awesome efficacy), and the advisory committee voted overwhelming in favor of approval (delayed because-FDA only requested non-clinical data in order to satisfy approval.)
-If the side effects with RIgel's drug are predicatable and reversable, should get FDA approval.